ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Stage IV Breast Cancer Clinical Trial

Official title:

Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients With Advanced Refractory Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00425672
• Other study ID #: 6308 (FH/UWCC ID)
• Secondary ID: NCI-2010-0080012
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 2005

Study information

• Verified date: November 2018
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: ONTAK may be able to help reduce the type of cells that prevent other types of immune cells from attacking the breast cancer cells.

PURPOSE: This phase I/II trial is studying the safety of ONTAK and its possible side effects to see how well it works in treating patients with advanced breast cancer that did not respond to previous treatment.

Description:

PRIMARY OBJECTIVES:

I. To evaluate the safety of ONTAK infusion in patients with advanced refractory breast cancer.

II. To evaluate the effect of ONTAK administration on peripheral blood T-regulatory cells.

SECONDARY OBJECTIVES:

I. To evaluate the incidence of IL-2R expression in tumor samples and investigate the correlation of tumor IL-2R expression and tumor response to ONTAK therapy.

II. To evaluate levels of circulating sIL-2R before and after ONTAK therapy. III. To evaluate the effect of ONTAK on endogenous tumor specific immunity. IV. To evaluate the potential anti-tumor effects of ONTAK in patients with advanced refractory breast cancer.

OUTLINE:

Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year.

Other known NCT identifiers

• NCT00364208

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. primary completion date: April 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with advanced stage refractory breast cancer

• Progressive or relapsed disease following standard therapy

• Patients must have measurable disease that can include, but is not limited to bone; specifically, patients must have measurable extraskeletal disease that can be accurately measured in at least one dimension as >= 20 mm with conventional CT techniques or >= 10 mm with spiral CT scan; measurable (bi-dimensional) chest wall disease will also be allowed

• Patients must be at least 14 days out from last cytotoxic chemotherapy; patients on bisphosphonates are eligible

• White blood cell count (WBC) > 3.0 THOU/ul

• ANC > 1.0 THOU/ul

• Platelets >= 100 THOU/ul

• Serum creatinine =< 2.0 mg/dL or creatinine clearance (calculated) >= 60 ml/min

• ALT/AST =< 2.0 x upper limit of normal

• Total bilirubin =< 1.5 x upper limit of normal

• Albumin >= 3.0 g/dL

• Subjects must have a Performance Status Score (ECOG Scale) =< 2

• Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment

• Men and women of reproductive ability must agree to contraceptive use during the study and for 1month after ONTAK treatment is discontinued

Exclusion Criteria:

• Prior treatment with ONTAK (DAB389 IL-2) or DAB486 IL-2

• Known history of hypersensitivity to diphtheria toxin or IL-2

• Active autoimmune disease

• Known history of pulmonary disease except controlled asthma

• History of or pre-existing, cardiovascular disease as defined by New York Heart Association (NYHA) Class III-IV categorization

• Pregnant or breast-feeding women

Related Conditions & MeSH terms

• Breast Neoplasms
• Breast Neoplasms, Male
• Male Breast Cancer
• Recurrent Breast Cancer
• Stage IIIA Breast Cancer
• Stage IIIB Breast Cancer
• Stage IIIC Breast Cancer
• Stage IV Breast Cancer

Intervention

Biological:
• ONTAK
Given IV

Other:
• flow cytometry
Correlative studies
• immunohistochemistry staining method
Correlative studies
• enzyme-linked immunosorbent assay
Correlative studies
• laboratory biomarker analysis
Correlative studies

Genetic:
• protein expression analysis
Correlative studies

Locations

Country	Name	City	State
United States	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
University of Washington	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Evaluated by Collecting Study Related Toxicity as Assessed by CTCAE v3.0	Subjects are monitored for the development of end organ damage by assessing adverse events with serum chemistries, liver function studies, serum albumin, complete blood counts, symptom assessment, and physical exams performed at every cycle until 3 weeks after the final dose of ONTAK. All adverse events for all systems are graded on a scale of 1-5 using CTCAE v3.0.	7 Days after last dose of ONTAK
Primary	Efficacy of ONTAK in Depleting T-regulatory Cells as a Decrease in Peripheral Blood Tregs Using Flow Cytometry	The efficacy of ONTAK in depleting Tregs will be defined as a decrease in peripheral blood Tregs by 25% of each individual subject's baseline. All subjects will undergo blood draws at baseline and post ONTAK infusions at designated time points. Tregs from the peripheral blood will be quantitated using flow cytometry.	21 days after cycle 6
Secondary	Incidence of Interleukin-2 (IL-2) and IL-2 Receptor (IL-2R) Expression in Tumor Samples by Immunohistochemical (IHC) Analysis	The incidence of IL-2 expression and its receptor complex, IL-2R in tumor samples will be evaluated by IHC analysis. Tumor sections will be interpreted as either positive or negative.	21 days after cycle 6
Secondary	Presence of Circulating sIL-2R in the Peripheral Blood	Evaluate levels of circulating sIL-2R (pg/ml) in the peripheral blood assessed before and after ONTAK therapy. Changes from baseline will be tabulated.	21 days after cycle 6
Secondary	Presence of Endogenous Tumor-specific Immunity	Evaluate the effect of ONTAK on endogenous tumor specific immunity	21 days after cycle 6
Secondary	Anti-tumor Effects of ONTAK Determined by Tumor Response and Progression	Anti-tumor effects of ONTAK will be determined by evaluating tumor response and progression per RECIST. An objective response to ONTAK will be defined as achieving a CR or PR. Analysis of the data will include determination of complete (CR) and partial response (PR) rates, as well as stable (SD) and progressive disease (PD).	21 days after cycle 6